| Entry |
|
|---|
| Name |
Ribociclib succinate (USAN);
Kisqali (TN)
|
|---|
| Product |
|
|---|
| Formula |
C23H30N8O. C4H6O4
|
|---|
| Exact mass |
552.2809
|
|---|
| Mol weight |
552.6253
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02943 CDK4/6 inhibitor
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG02084): | D10979<US> |
| Product (mixture): | D11068<US> |
|
|---|
| Efficacy |
Antineoplastic, Cyclin-dependent kinase (CDK) inhibitor |
|---|
| Disease |
Breast cancer (HR-positive, HER2-negative) [DS: H00031] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE42 Ribociclib
D10979 Ribociclib succinate (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Ribociclib
D10979 Ribociclib succinate (USAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
CMGC group
CDK4/6
D10979 Ribociclib succinate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10979
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10979
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10979
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10979
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10979
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 40
1 N5x N 18.4296 -14.9311
2 C8y C 18.4296 -16.3336
3 N5x N 17.2375 -17.0349
4 C8y C 15.9752 -16.3336
5 C8y C 15.9752 -14.9311
6 C8x C 17.2375 -14.2298
7 N4y N 14.6427 -16.7544
8 C8y C 13.8713 -15.6323
9 C8x C 14.6427 -14.5103
10 N1b N 19.6218 -17.0349
11 C8y C 20.8140 -16.3336
12 C8x C 20.8140 -14.9311
13 C8x C 22.0763 -14.2298
14 C8y C 23.2685 -14.9311
15 C8x C 23.2685 -16.3336
16 N5x N 22.0763 -17.0349
17 N1y N 24.4607 -14.2298
18 C1x C 24.4607 -12.8272
19 C1x C 25.7230 -12.1259
20 N1x N 26.9152 -12.8272
21 C1x C 26.9152 -14.2298
22 C1x C 25.7230 -14.9311
23 C5a C 12.4687 -15.6323
24 C1y C 14.2219 -18.0868
25 C1x C 15.0635 -19.2089
26 C1x C 14.2219 -20.3309
27 C1x C 12.8895 -19.9102
28 C1x C 12.8895 -18.5076
29 O5a O 11.7674 -16.8245
30 N1c N 11.7674 -14.4402
31 C1a C 10.3649 -14.4402
32 C1a C 12.4687 -13.2480
33 O6a O 27.5100 -18.8300
34 C6a C 28.7224 -18.1300
35 C1b C 29.9349 -18.8300
36 C1b C 31.1473 -18.1300
37 C6a C 32.3597 -18.8300
38 O6a O 33.5722 -18.1300
39 O6a O 28.7224 -16.7302
40 O6a O 32.3597 -20.2299
BOND 43
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 2
10 5 9 1
11 2 10 1
12 10 11 1
13 11 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 15 16 2
18 11 16 1
19 14 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 17 22 1
26 8 23 1
27 7 24 1
28 24 25 1
29 25 26 1
30 26 27 1
31 27 28 1
32 24 28 1
33 23 29 2
34 23 30 1
35 30 31 1
36 30 32 1
37 33 34 1
38 34 35 1
39 35 36 1
40 36 37 1
41 37 38 1
42 34 39 2
43 37 40 2
|
|---|
